Defence Therapeutics Inc.
DTCFF
$0.5198
-$0.0309-5.61%
OTC PK
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -15.36% | -29.24% | 54.85% | -0.05% | 83.90% |
| Total Depreciation and Amortization | -3.15% | -2.31% | -63.38% | 112.57% | 227.45% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 28.63% | 44.84% | 20.02% | 54.69% | -98.38% |
| Change in Net Operating Assets | -840.96% | -128.60% | -19.16% | 126.23% | -73.47% |
| Cash from Operations | -191.25% | -844.93% | 116.48% | 44.28% | 31.87% |
| Capital Expenditure | -- | -- | -- | 107.82% | -- |
| Sale of Property, Plant, and Equipment | -100.00% | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -100.00% | -- | -- | 107.82% | -- |
| Total Debt Issued | -- | -100.00% | -70.00% | -- | -- |
| Total Debt Repaid | 82.63% | -365.83% | -256.41% | 0.00% | -213.04% |
| Issuance of Common Stock | 426.88% | -- | -- | -98.97% | 242.26% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -1,056.07% | -- | -- | 100.00% | -245.15% |
| Cash from Financing | 492.80% | 5,032.98% | -122.49% | -95.72% | 237.14% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 271,720.00% | -100.91% | 116.34% | -375.93% | 116.52% |